Artemisinin and geniposide suppress Toll-like receptor 4 (TLR4) to inhibit the NF-κB and MAPK signaling pathways to ameliorate AD (Liu W. et al., 2015; Qiang et al., 2018). Here, TLR4 is linked to Alzheimer disease.